PSYCHOPHARMACOLOGY DRUGS THE
BRAIN AND BEHAVIOR TEST BANK 2026
SOLVED QUESTIONS FULL RATIONALE SET
⩥ amphetamine. Answer: MOA = complex; indirectly causes release of
monoamines, inhibits reuptake of monoamines, and inhibits monoamine
oxidase; contraindicated in hyperthyroidism, glaucoma, and
cardiovascular conditions
⩥ methylphenidate. Answer: MOA = DA/NE reuptake inhibitor; similar
issues to amphetamine; longer half-life than amphetamine
⩥ schedule I drugs. Answer: no medical use w/ high potential for
dependence
⩥ THC. Answer: MOA = cannabinoid receptor (CB1) agonist; Tx of
nausea/vomiting, epilepsy, and glaucoma; contraindicated in patients
taking anticoagulants/anti-platelet drugs and CNS depressants
⩥ psychedelics. Answer: MOA = 5-HT2A agonists; includes psilocybin,
mescaline, LSD, DMT, MDMA; Tx of Tx-resistant depression, OCD,
PTSD, anxiety
, ⩥ heroin. Answer: MOA = pure opioid agonist; produces analgesia (via
opioid agonism) and produces euphoria (via removal of tonic (-) on DA
release)
⩥ pure opioid agonists. Answer: MOA = opioid agonists; Tx of mild to
severe pain; listed in order of less to more potent: [1] codeine, [2]
tramadol, [3] hydrocodone, [4] meperidine, [5] morphine, [6] oxycodone
⩥ euphoria. Answer: induced by opioids via removal of tonic inhibition
on DA release
⩥ constipation/urinary retention. Answer: induced by opioids due to
ADH release
⩥ contraindications for opioids. Answer: patients with history of
substance use disorder, head injury, and pregnancy
⩥ methadone. Answer: produces fewer euphoric effects than heroin in
opioid dependent patients; used in maintenance of opioid use disorder
⩥ pure opioid antagonists. Answer: MOA = opioid antagonists
⩥ naloxone. Answer: competitive opioid receptor antagonist; used in
emergent overdose scenarios
BRAIN AND BEHAVIOR TEST BANK 2026
SOLVED QUESTIONS FULL RATIONALE SET
⩥ amphetamine. Answer: MOA = complex; indirectly causes release of
monoamines, inhibits reuptake of monoamines, and inhibits monoamine
oxidase; contraindicated in hyperthyroidism, glaucoma, and
cardiovascular conditions
⩥ methylphenidate. Answer: MOA = DA/NE reuptake inhibitor; similar
issues to amphetamine; longer half-life than amphetamine
⩥ schedule I drugs. Answer: no medical use w/ high potential for
dependence
⩥ THC. Answer: MOA = cannabinoid receptor (CB1) agonist; Tx of
nausea/vomiting, epilepsy, and glaucoma; contraindicated in patients
taking anticoagulants/anti-platelet drugs and CNS depressants
⩥ psychedelics. Answer: MOA = 5-HT2A agonists; includes psilocybin,
mescaline, LSD, DMT, MDMA; Tx of Tx-resistant depression, OCD,
PTSD, anxiety
, ⩥ heroin. Answer: MOA = pure opioid agonist; produces analgesia (via
opioid agonism) and produces euphoria (via removal of tonic (-) on DA
release)
⩥ pure opioid agonists. Answer: MOA = opioid agonists; Tx of mild to
severe pain; listed in order of less to more potent: [1] codeine, [2]
tramadol, [3] hydrocodone, [4] meperidine, [5] morphine, [6] oxycodone
⩥ euphoria. Answer: induced by opioids via removal of tonic inhibition
on DA release
⩥ constipation/urinary retention. Answer: induced by opioids due to
ADH release
⩥ contraindications for opioids. Answer: patients with history of
substance use disorder, head injury, and pregnancy
⩥ methadone. Answer: produces fewer euphoric effects than heroin in
opioid dependent patients; used in maintenance of opioid use disorder
⩥ pure opioid antagonists. Answer: MOA = opioid antagonists
⩥ naloxone. Answer: competitive opioid receptor antagonist; used in
emergent overdose scenarios
